CCN1 and osteosarcoma: We found that the addition of FPP, but not GGPP could reverse the down-modulation of CYR61 in simvastatin-treated MSC, in contrast with the report of Fromigue and colleagues in osteosarcoma [44], which may be explained by the cell-type and context dependent function and regulation of CYR61.